

ISSUE @ A GLANCE



Risk assessment and its management: from SCORE to statins, ezetimibe to PCSK inhibitors
T.F. Lüscher

2233

CardioPulse

Basic Science and Cardiology I: Basics
J. Ozkan

2237

Basic Science and Cardiology II: Funding
J. Ozkan

2239

Andreas Baumbach MD FESC FRCP
M. Nicholls

2240

My 10th TAVI Anniversary
A.M. Kasel

2242

Delirium in cardiac patients
S. Grotti and G. Falsini

2244

CURRENT OPINION

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

U. Landmesser, M. John Chapman, M. Farnier, B. Gencer, S. Gielen, G.K. Hovingh, T.F. Lüscher, D. Sinning, L. Tokgözoğlu, O. Wiklund, J.L. Zamorano, F.J. Pinto, and A.L. Catapano on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

2245

Editorial

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic

M.S. Sabatine

2256



Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention
M.B. Mortensen and E. Falk

2259

CLINICAL RESEARCH



Coronary artery disease

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial

N. Hagiwara, E. Kawada-Watanabe, R. Koyanagi, H. Arashi, J. Yamaguchi, K. Nakao, T. Tobaru, H. Tanaka, T. Oka, Y. Endoh, K. Saito, T. Uchida, K. Matsui, and H. Ogawa

2264


Editorial

Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?

K.H. Humphries and G.B.J. Mancini

2276

Heart failure/cardiomyopathy



Patients at risk							
Placebo	201	194	185	181	175	167	165
Vitamin D	199	194	188	180	174	166	160

Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily

A. Zittermann, J.B. Ernst, S. Prokop, U. Fuchs, J. Dreier, J. Kuhn, C. Knabbe, I. Birschmann, U. Schulz, H.K. Berthold, S. Pilz, I. Gouni-Berthold, J.F. Gummert, M. Dittrich, and J. Bögermann

2279

Editorial

Vitamin D supplementation in heart failure: case closed?

R.A. de Boer, L.M.G. Meems, and D.J. van Veldhuisen

2287

Prevention and epidemiology

Long-term exposure to road traffic noise, ambient air pollution, and cardiovascular risk factors in the HUNT and lifelines cohorts

Y. Cai, A.L. Hansell, M. Blangiardo, P.R. Burton, BioSHARe, K. de Hoogh, D. Doiron, I. Fortier, J. Gulliver, K. Hveem, S. Mbatchou, D.W. Morley, R.P. Stolk, W.L. Zijlema, P. Elliott, and S. Hodgson

2290


Editorial

Environmental stressors and cardiovascular disease: the evidence is growing

T. Münzel, J. Herzog, F.P. Schmidt, and M. Sørensen

2297

Hypertension



Risk for hypertension crosses generations in the community: a multi-generational cohort study

T.J. Niiiranen, E.L. McCabe, M.G. Larson, M. Henglin, N.K. Lakdawala, R.S. Vasan, and S. Cheng

2300

Editorial

Understanding the role of genetics in hypertension

R.S. Patel, S. Masi, and S. Taddei

2309

CARDIOVASCULAR FLASHLIGHTS

Primary echinococcus infection of the heart: a rare type of cystic echinococcosis

T.N.C. Padmanabhan, K.V.K. Kumar, M. Sadiq Azam, and A. Kumar Bilolikar

2255

Large multiple tuberous xanthomas presenting with severe coronary artery disease

A. Maskey, A. Hirachan, D. Yadav, and M. Roka

2313



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site

<https://academic.oup.com/eurheartj>



www.eurheartj.org